- Home
- GDDY vs BIIB Comparison
GDDY vs BIIB Comparison
Compare GDDY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDDY
- BIIB
- Stock Information
- Founded
- GDDY 1997
- BIIB 1978
- Country
- GDDY United States
- BIIB United States
- Employees
- GDDY N/A
- BIIB N/A
- Industry
- GDDY EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GDDY Technology
- BIIB Health Care
- Exchange
- GDDY Nasdaq
- BIIB Nasdaq
- Market Cap
- GDDY 20.0B
- BIIB 18.7B
- IPO Year
- GDDY 2015
- BIIB 1991
- Fundamental
- Price
- GDDY $133.78
- BIIB $149.17
- Analyst Decision
- GDDY Buy
- BIIB Buy
- Analyst Count
- GDDY 13
- BIIB 26
- Target Price
- GDDY $202.31
- BIIB $182.82
- AVG Volume (30 Days)
- GDDY 1.5M
- BIIB 1.8M
- Earning Date
- GDDY 10-30-2025
- BIIB 10-30-2025
- Dividend Yield
- GDDY N/A
- BIIB N/A
- EPS Growth
- GDDY N/A
- BIIB 31.67
- EPS
- GDDY 5.60
- BIIB 10.45
- Revenue
- GDDY $4,752,100,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- GDDY $9.75
- BIIB $2.00
- Revenue Next Year
- GDDY $7.21
- BIIB N/A
- P/E Ratio
- GDDY $23.90
- BIIB $14.31
- Revenue Growth
- GDDY 7.93
- BIIB 3.36
- 52 Week Low
- GDDY $131.29
- BIIB $110.04
- 52 Week High
- GDDY $216.00
- BIIB $194.13
- Technical
- Relative Strength Index (RSI)
- GDDY 34.13
- BIIB 56.57
- Support Level
- GDDY $133.50
- BIIB $135.39
- Resistance Level
- GDDY $139.44
- BIIB $160.20
- Average True Range (ATR)
- GDDY 3.48
- BIIB 4.43
- MACD
- GDDY -0.25
- BIIB 0.56
- Stochastic Oscillator
- GDDY 14.85
- BIIB 54.23
About GDDY GoDaddy Inc.
GoDaddy provides domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.